TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

SPINRAZA

NUSINERSEN SODIUM
Approved 2016-12-23

Spinraza (nusinersen sodium) is an antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA). The therapy is approved for use in both pediatric and adult patient populations. It is specifically designed to treat SMA associated with mutations in chromosome 5q that lead to a deficiency in survival motor neuron (SMN) protein.

Source: FDA Label • Biogen • Survival Motor Neuron-2-directed RNA Interaction

How SPINRAZA Works

Spinraza is an antisense oligonucleotide that targets survival motor neuron-2 (SMN2) messenger ribonucleic acid (mRNA) transcripts. The drug increases the inclusion of exon 7 in these transcripts, which allows for the production of full-length SMN protein. By increasing the levels of this protein, the medication addresses the deficiency caused by chromosome 5q mutations.

Source: FDA Label
3
Indications
--
Phase 3 Trials
1
Priority Reviews
9
Years on Market

Details

Status
Prescription
First Approved
2016-12-23
Routes
INTRATHECAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: NUSINERSEN SODIUM

SPINRAZA Approval History

Loading approval history...

What SPINRAZA Treats

2 indications

SPINRAZA is approved for 2 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Spinal muscular atrophy (SMA) in pediatric patients
  • Spinal muscular atrophy (SMA) in adult patients
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SPINRAZA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients

SPINRAZA Patents & Exclusivity

Latest Patent: Mar 2036

Patents (20 active)

US12013403 Expires Mar 4, 2036
US10436802 Expires Sep 11, 2035
US9926559 Expires Jan 9, 2034
US8361977 Expires Dec 23, 2030
US8980853 Expires Nov 24, 2030
US9717750 Expires Jun 17, 2030
US7838657 Expires Jul 11, 2027
+ 10 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.